nuclear-news

The idea of nuclear catastrophe a money spinner for pharmaceutical companies

to address the skin and lung injuries that arise from acute exposure to high levels of ionizing radiation – the type of radiation that results from a nuclear blast.

BARDA Supports Development Of Drugs To Protect Against Radiation Biomed Middle East By: Ash on February 18, 2011 Two contracts for advanced development of drugs to treat skin and lung injuries associated with acute radiation syndrome (ARS) were awarded this week by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). These contracts are the first by BARDA to address the skin and lung injuries that arise from acute exposure to high levels of ionizing radiation – the type of radiation that results from a nuclear blast.

The contracts were awarded to Aeolus Pharmaceuticals Inc., of Mission Viejo, Calif., and U.S. Biotest Inc., of San Luis Obispo, Calif., and support research studies and manufacturing efforts by each company in developing their respective drugs.

The Aeolus contract is valued at $10.4 million for the first year and can be extended for a total of five years and up to a total of $118.4 million. Aeolus is developing a broad-spectrum antioxidant drug known as AEOL 10150. This drug was designed originally to reduce the damage caused by radiation during cancer treatments. For BARDA, the drug will be developed for use in treating lung injuries associated with acute radiation syndrome, known as pulmonary acute radiation syndrome or lung-ARS…..

These contracts are part of the HHS radiological and nuclear threats preparedness strategy.

February 19, 2011 - Posted by Christina Macpherson | business and costs, USA